The multi-kinase inhibitor regorafenib did not improve overall survival (OS) compared with standard treatment for patients with newly diagnosed unmethylated or recurrent glioblast ...

A team of researchers from Brown University Health and Brown University has uncovered an important clue in the fight against ...

A new glioblastoma treatment showed tumour elimination and durable protection in a preclinical model. Discover what this ...

A new grant from the American Cancer Society (ACS) will fund research into a new strategy for targeting glioblastoma at MUSC ...

Combining microchip engineering techniques with cutting-edge gene profiling, scientists at Columbia University have developed ...

Glioblastoma, the most aggressive malignant brain tumor in adults, is not an isolated lesion, but a disease that destabilizes ...

Add Yahoo as a preferred source to see more of our stories on Google. Before her death earlier this month, Madeleine Sophie Wickham, known by her pen name Sophie Kinsella, was known for creating ...

Complete Response With Alpelisib and Trastuzumab in a Patient With Estrogen Receptor–/Progesterone Receptor–Negative, Human Epidermal Growth Factor Receptor 2 ...

Glioblastoma, the most aggressive and deadly type of brain cancer, is known to have a very poor prognosis — but a new study suggests that a pain-relieving drug could extend survival. Researchers at ...

Glioblastoma cancer is a grade 4 primary brain tumor that grows aggressively within brain tissue, making it the most common malignant brain tumor in adults. Symptoms range from persistent headaches ...

The MarketWatch News Department was not involved in the creation of this content. HOUSTON, March 18, 2026 /PRNewswire/ -- Diakonos Oncology Corp., a clinical-stage biotechnology company developing a ...